Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Clinical Trial ID NCT01308294

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: Peptide vaccines in cancer therapy.	Oncoimmunology	2012	1.17
2	A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma.	Clin Cancer Res	2009	1.12
3	The CD4-like molecule LAG-3, biology and therapeutic applications.	Expert Opin Ther Targets	2011	1.00
4	Clinical impact of checkpoint inhibitors as novel cancer therapies.	Drugs	2014	0.99
5	Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.	Semin Immunol	2010	0.96
6	Immune checkpoint inhibitors: therapeutic advances in melanoma.	Ann Transl Med	2015	0.87
7	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81
8	Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.	Hum Vaccin Immunother	2014	0.81
9	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.	Oncologist	2015	0.81
10	Cancer testis antigen and immunotherapy.	Immunotargets Ther	2013	0.76